Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
KNSA Stock Summary
Top 10 Correlated ETFs
KNSA
In the News

The Top 7 Growth Stocks in Biotech
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 125% and 31.18%, respectively, for the quarter ended December 2022.

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023
HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2022 financial results and recent portfolio execution.

Kiniksa: Steady Progress With Arcalyst, But Still Pretty Unexciting
Kiniksa did very well with arcalyst, buying low, selling well. However, its pipeline does not excite investors.

Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
HAMILTON, Bermuda, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference
HAMILTON, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Bank of America Securities 2022 Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 10:15 a.m. Eastern Time.

Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference
HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 10:05 a.m. Eastern Time.

Are Medical Stocks Lagging Kiniksa Pharmaceuticals (KNSA) This Year?
Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Assertio (ASRT) have performed compared to their sector so far this year.

Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's Why
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Q3 2022 Earnings Call Transcript
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Rachel Frank – Head-Investor Relations Sanj K.
KNSA Financial details
KNSA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0.56 | 3.17 | |
Net income per share | -3.49 | -2.99 | -2.61 | -2.3 | 2.64 | |
Operating cash flow per share | -2.74 | -2.93 | -2.21 | -1.84 | 0.08 | |
Free cash flow per share | -2.92 | -2.99 | -2.21 | -2.14 | 0.08 | |
Cash per share | 10.4 | 4.32 | 5.23 | 2.66 | 2.75 | |
Book value per share | 9.45 | 4.17 | 5.04 | 2.7 | 5.71 | |
Tangible book value per share | 9.45 | 4.17 | 5.04 | 2.42 | 5.45 | |
Share holders equity per share | 9.45 | 4.17 | 5.04 | 2.7 | 5.71 | |
Interest debt per share | 0 | 0.03 | 0.11 | 0.09 | 0.09 | |
Market cap | 829.99M | 597.79M | 1.09B | 807.15M | 1.04B | |
Enterprise value | 758.01M | 550.86M | 985.71M | 690.73M | 922.55M | |
P/E ratio | -8.04 | -3.69 | -6.77 | -5.11 | 5.67 | |
Price to sales ratio | 0 | 0 | 0 | 20.94 | 4.72 | |
POCF ratio | -10.25 | -3.77 | -8 | -6.39 | 178.98 | |
PFCF ratio | -9.62 | -3.7 | -7.99 | -5.5 | 182.28 | |
P/B Ratio | 2.97 | 2.65 | 3.5 | 4.36 | 2.62 | |
PTB ratio | 2.97 | 2.65 | 3.5 | 4.36 | 2.62 | |
EV to sales | 0 | 0 | 0 | 17.92 | 4.19 | |
Enterprise value over EBITDA | -7.35 | -3.4 | -6.41 | -4.48 | 2.58 | |
EV to operating cash flow | -9.36 | -3.48 | -7.22 | -5.47 | 158.87 | |
EV to free cash flow | -8.78 | -3.41 | -7.2 | -4.71 | 161.79 | |
Earnings yield | -0.12 | -0.27 | -0.15 | -0.2 | 0.18 | |
Free cash flow yield | -0.1 | -0.27 | -0.13 | -0.18 | 0.01 | |
Debt to equity | 0.15 | 0.13 | 0.12 | 0.26 | 0.16 | |
Debt to assets | 0.13 | 0.11 | 0.11 | 0.21 | 0.14 | |
Net debt to EBITDA | 0.7 | 0.29 | 0.7 | 0.76 | -0.33 | |
Current ratio | 7.37 | 8.68 | 10.46 | 4.38 | 5.16 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0.78 | 0.98 | 0.85 | 0.8 | 0.03 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 2.58 | 0.3 | |
Intangibles to total assets | 0 | 0 | 0 | 0.08 | 0.04 | |
Capex to operating cash flow | 0.07 | 0.02 | 0 | 0.16 | -0.02 | |
Capex to revenue | 0 | 0 | 0 | -0.53 | 0 | |
Capex to depreciation | -18.5 | -1.55 | -0.12 | -8.67 | -0.04 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0.65 | 0.11 | |
Graham number | 27.26 | 16.76 | 17.21 | 11.82 | 18.43 | |
ROIC | -0.65 | -1.08 | -1.34 | 11.28 | -0.69 | |
Return on tangible assets | -0.32 | -0.64 | -0.46 | -0.74 | 0.42 | |
Graham Net | 8.96 | 3.78 | 4.62 | 2.03 | 2.12 | |
Working capital | 271.2M | 213.8M | 301.4M | 151.62M | 195.99M | |
Tangible asset value | 279.27M | 225.42M | 311.94M | 165.79M | 377.9M | |
Net current asset value | 271.05M | 212.52M | 295.72M | 148.68M | 179.54M | |
Invested capital | 0 | 0.01 | 0.02 | 0.03 | 0.01 | |
Average receivables | 0 | 0 | 0 | 1.99M | 8.32M | |
Average payables | 6.07M | 8.31M | 3.1M | 1.19M | 4.88M | |
Average inventory | 0 | 0 | 0 | 1.84M | 12.64M | |
Days sales outstanding | 0 | 0 | 0 | 37.74 | 20.99 | |
Days payables outstanding | 0 | 0 | 0 | 74.93 | 125.93 | |
Days of inventory on hand | 0 | 0 | 0 | 147.4 | 344.34 | |
Receivables turnover | 0 | 0 | 0 | 9.67 | 17.39 | |
Payables turnover | 0 | 0 | 0 | 4.87 | 2.9 | |
Inventory turnover | 0 | 0 | 0 | 2.48 | 1.06 | |
ROE | -0.37 | -0.72 | -0.52 | -0.85 | 0.46 | |
Capex per share | -0.18 | -0.06 | 0 | -0.3 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.18 | 0.27 | 0.47 | 1.43 | 0.89 | |
Net income per share | -0.44 | -0.53 | -0.36 | 3.23 | 0.06 | |
Operating cash flow per share | -0.42 | -0.27 | -0.53 | 0.89 | -0.17 | |
Free cash flow per share | -0.42 | -0.28 | -0.53 | 0.89 | -0.17 | |
Cash per share | 2.92 | 2.64 | 2.11 | 2.89 | 2.75 | |
Book value per share | 3.12 | 2.68 | 2.4 | 5.53 | 5.71 | |
Tangible book value per share | 2.83 | 2.4 | 2.13 | 5.26 | 5.45 | |
Share holders equity per share | 3.12 | 2.68 | 2.4 | 5.53 | 5.71 | |
Interest debt per share | 0.1 | 0.09 | 0.08 | 0.1 | 0.09 | |
Market cap | 782.07M | 811.79M | 687.22M | 891.67M | 1.04B | |
Enterprise value | 598.63M | 695.37M | 629.3M | 722.62M | 922.55M | |
P/E ratio | -6.4 | -5.59 | -6.81 | 0.99 | 58.25 | |
Price to sales ratio | 64.66 | 43.31 | 21.35 | 8.99 | 16.8 | |
POCF ratio | -27.43 | -42.99 | -18.65 | 14.37 | -89.78 | |
PFCF ratio | -27.38 | -42.42 | -18.65 | 14.37 | -90.03 | |
P/B Ratio | 3.65 | 4.39 | 4.13 | 2.32 | 2.62 | |
PTB ratio | 3.65 | 4.39 | 4.13 | 2.32 | 2.62 | |
EV to sales | 49.49 | 37.1 | 19.55 | 7.29 | 14.91 | |
Enterprise value over EBITDA | -19.95 | -19.65 | -27.85 | 15.2 | 2.62 | |
EV to operating cash flow | -21 | -36.82 | -17.08 | 11.65 | -79.7 | |
EV to free cash flow | -20.96 | -36.34 | -17.08 | 11.65 | -79.92 | |
Earnings yield | -0.04 | -0.04 | -0.04 | 0.25 | 0 | |
Free cash flow yield | -0.04 | -0.02 | -0.05 | 0.07 | -0.01 | |
Debt to equity | 0.18 | 0.26 | 0.39 | 0.2 | 0.16 | |
Debt to assets | 0.15 | 0.21 | 0.28 | 0.17 | 0.14 | |
Net debt to EBITDA | 6.11 | 3.29 | 2.56 | -3.56 | -0.33 | |
Current ratio | 6.32 | 4.38 | 3.95 | 4.28 | 5.16 | |
Interest coverage | 0 | 0 | -685.85 | 144.14 | 0 | |
Income quality | 0.93 | 0.52 | 1.46 | 0.28 | -2.59 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 1.59 | 1.46 | 0.65 | 0.17 | 0.23 | |
Intangibles to total assets | 0.08 | 0.08 | 0.08 | 0.04 | 0.04 | |
Capex to operating cash flow | 0 | 0.01 | 0 | 0 | 0.01 | |
Capex to revenue | 0 | -0.01 | 0 | 0 | 0 | |
Capex to depreciation | -0.08 | -0.38 | 0 | -0.04 | -0.14 | |
Stock based compensation to revenue | 0.51 | 0.33 | 0.19 | 0.06 | 0.1 | |
Graham number | 5.59 | 5.64 | 4.44 | 20.04 | 2.87 | |
ROIC | 0.24 | 2.6 | -0.25 | 2.08 | -1.46 | |
Return on tangible assets | -0.13 | -0.17 | -0.12 | 0.51 | 0.01 | |
Graham Net | 2.43 | 2.02 | 1.58 | 2.02 | 2.12 | |
Working capital | 183.09M | 151.62M | 148.4M | 185.32M | 195.99M | |
Tangible asset value | 194.55M | 165.79M | 147.24M | 365.51M | 377.9M | |
Net current asset value | 178.7M | 148.68M | 134.04M | 165.87M | 179.54M | |
Invested capital | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | |
Average receivables | 2.89M | 3.6M | 16.71M | 0 | 11.91M | |
Average payables | 2.9M | 1.76M | 2.63M | 0 | 4.68M | |
Average inventory | 5.99M | 4.64M | 8.45M | 0 | 18.11M | |
Days sales outstanding | 23.99 | 19.13 | 82.31 | 10.13 | 18.41 | |
Days payables outstanding | 53.64 | 43.48 | 24.41 | 11.44 | -115.28 | |
Days of inventory on hand | 182.34 | 85.53 | 95.41 | 113.83 | -315.21 | |
Receivables turnover | 3.75 | 4.7 | 1.09 | 8.88 | 4.89 | |
Payables turnover | 1.68 | 2.07 | 3.69 | 7.87 | -0.78 | |
Inventory turnover | 0.49 | 1.05 | 0.94 | 0.79 | -0.29 | |
ROE | -0.14 | -0.2 | -0.15 | 0.58 | 0.01 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
KNSA Frequently Asked Questions
What is Kiniksa Pharmaceuticals, Ltd. stock symbol ?
Kiniksa Pharmaceuticals, Ltd. is a BM stock and trading under the symbol KNSA
What is Kiniksa Pharmaceuticals, Ltd. stock quote today ?
Kiniksa Pharmaceuticals, Ltd. stock price is $11.32 today.
Is Kiniksa Pharmaceuticals, Ltd. stock public?
Yes, Kiniksa Pharmaceuticals, Ltd. is a publicly traded company.